ストックスクリーナーアプリを入手
37.27
4.50%
1.605
アフターアワーズ：
37.31
0.035
+0.09%
Revolution Medicines Inc (RVMD) 最新ニュース
RSI Crosses Above 30 for Revolution Medicines Inc. — Reversal in Sight2025 Dividend Review & Low Risk Profit Maximizing Plans - thegnnews.com
Revolution Medicines outlines $1.03B–$1.09B net loss guidance for 2025 amid expanded global RAS portfolio strategy - MSN
Healthcare Sector Analysts Offer Insights on Revolution Medicines, Astria Therapeutics, and AbbVie - AInvest
Revolution Medicines’ SWOT analysis: promising cancer drug stock faces pivotal year - Investing.com
LifeSci Capital Initiates Revolution Medicines at Outperform With $80 Price Target - MarketScreener
Will Revolution Medicines Inc. Equity Warrant Bounce From 52 Week Low2025 Retail Activity & Weekly Setup with High ROI Potential - metal.it
What is Revolution Medicines Inc.’s valuation compared to sector2025 Major Catalysts & Weekly Return Optimization Plans - thegnnews.com
Wells Fargo Initiates Revolution Medicines at Overweight With $67 Price Target - MarketScreener
Revolution Medicines initiated with an Overweight at Wells Fargo - TipRanks
Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress - MSN
Barclays Reaffirms Buy Rating on Revolution Medicines with $72 Price Target - AInvest
Revolution Medicines’ SWOT analysis: stock poised for growth amid clinical progress - Investing.com Canada
Is It Too Late to Sell Revolution Medicines Inc. Equity WarrantJuly 2025 EndofMonth & Step-by-Step Trade Execution Guides - mustnews.co.kr
Revolution Medicines Inc. Stock Poised for Technical Comeback2025 Key Highlights & AI Forecast Swing Trade Picks - beatles.ru
Revolution Medicines Receives FDA Breakthrough Therapy Designation for Elironrasib for Lung Cancer - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: FibroGen (FGEN), Revolution Medicines (RVMD) - The Globe and Mail
Revolution Medicines’ Earnings Call: Progress Amid Challenges - TipRanks
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $56 to $80 - 富途牛牛
Revolution Medicines (RVMD): A High-Risk, High-Reward Biotech Play in the RAS Oncology Space - AInvest
Contradictions Unveiled: RASolute 302 Study Progress and Efficacy Concerns in Latest Earnings Call - AInvest
Revolution Medicines Forecasts $1.03B-$1.09B Net Loss for 2025 Amid RAS Portfolio Expansion - AInvest
Earnings call transcript: Revolution Medicines Q2 2025 sees stock dip after earnings miss - Investing.com
Revolution Medicines August 2025 slides: advancing RAS inhibitor pipeline with promising data - Investing.com India
Revolution Medicines August 2025 slides: advancing RAS inhibitor pipeline with promising data By Investing.com - Investing.com South Africa
Revolution Medicines Advances RAS-Targeted Therapies, Reports Q2 Earnings - AInvest
Revolution Medicines Advances RAS-Targeted Therapies - TipRanks
Revolution Medicines Q2 2025 Earnings Call Transcript - MarketBeat
Revolution Medicines shares rise 2.13% after-hours after reporting strong Phase 3 trial progress and $2 billion funding agreement. - AInvest
Transcript : Revolution Medicines, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Revolution Medicines Doubles Down On Losses To Fuel New Drugs - Finimize
Earnings Flash: (RVMD) Revolution Medicines Q2 Loss $1.31 Vs. FactSet Est. $1.12 Loss - MarketScreener
Revolution Medicines Reports Wider Q2 Loss, Receives Breakthrough Therapy Designation for Elironrasib - AInvest
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress - GlobeNewswire
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025 - The Globe and Mail
Tango (TNGX) Q2 Revenue Drops 52% - The Motley Fool
Revolution Medicines shares rise 2.80% intraday after Tango Therapeutics reported dosing first patient in combination trial with Revolution Medicines RAS(ON) inhibitors. - AInvest
What To Expect From Revolution Medicines Inc (RVMD) Q2 2025 Earnings - Yahoo Finance
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewswire
Recovery Setup Building in Revolution Medicines Inc. Experts SayLow Risk Equity Screener With Results Shared - metal.it
What analysts say about Revolution Medicines Inc. stockInvest smarter and grow your wealth faster - Jammu Links News
What drives Revolution Medicines Inc. stock priceDiscover high-growth stocks for your portfolio - Jammu Links News
When is Revolution Medicines Inc. stock expected to show significant growthExplosive returns - Jammu Links News
Is it the right time to buy Revolution Medicines Inc. Equity Warrant stockCapitalize on market trends with confidence - Jammu Links News
How does Revolution Medicines Inc. compare to its industry peersSuperior stock growth - Jammu Links News
What is Revolution Medicines Inc. company’s growth strategyUnmatched market gains - Jammu Links News
Is Revolution Medicines Inc. a growth stock or a value stockRapidly growing investment returns - Jammu Links News
Published on: 2025-08-03 19:52:18 - Jammu Links News
Is Revolution Medicines Inc. Equity Warrant a growth stock or a value stockHigh-yield capital appreciation - Jammu Links News
How strong is Revolution Medicines Inc. company’s balance sheetDiscover high-return stocks for your portfolio - Jammu Links News
How many analysts rate Revolution Medicines Inc. Equity Warrant as a “Buy”Harness the power of proven investment plans - Jammu Links News
How volatile is Revolution Medicines Inc. Equity Warrant stock compared to the marketAccelerated earnings growth - Jammu Links News
What is the risk reward ratio of investing in Revolution Medicines Inc. Equity Warrant stockAchieve consistent profits with expert advice - Jammu Links News
Published on: 2025-08-03 11:06:26 - Jammu Links News
What are the latest earnings results for Revolution Medicines Inc. Equity WarrantMarket-leading growth rates - jammulinksnews.com
Is Revolution Medicines Inc. Equity Warrant stock overvalued or undervaluedTriple-digit return opportunities - Jammu Links News
Is Revolution Medicines Inc. a good long term investmentGet exclusive access to professional stock picks - Jammu Links News
What institutional investors are buying Revolution Medicines Inc. Equity Warrant stockDiscover high-return stocks for your portfolio - Jammu Links News
Is Revolution Medicines Inc. stock overvalued or undervaluedMarket-leading profit generation - Jammu Links News
0.95%
0.90%
大文字化:
|
ボリューム (24 時間):